文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

COVID-19 大流行前后院内心脏骤停生存率:高绩效医院是否保持高绩效

In-hospital cardiac arrest survival before and after the COVID-19 pandemic: Have higher performing hospitals stayed high-performing?
PubMed 文献 · Resuscitation · 2024-08-20
一句话结论在 Get With The Guidelines®-复苏注册的 243 家医院中,大流行前与大流行后院内心脏骤停风险标化出院生存率呈良好相关(相关系数 0.55),黑人/西班牙裔患者比例不同的医院间该相关性无显著差异(交互作用 P=0.69)。

研究基于 Get With The Guidelines®-复苏注册,纳入大流行前(2017-2019)和大流行后(2020 年 7 月-2022)均参与注册至少 2 年、且两个时期均至少有 20 例院内心脏骤停的 243 家医院,共 122,561 例院内心脏骤停(大流行前 57,601 例,大流行后 64,960 例)。采用以医院为随机效应的多变量层次模型,调整患者和骤停特征后计算各医院大流行前后院内心脏骤停风险标化出院生存率。大流行前平均风险标化出院生存率为 26.8%(SD 5.2%),大流行后为 21.7%(SD 5.5%),两者相关系数为 0.55。按黑人/西班牙裔院内心脏骤停患者比例三分位分组,上、中、下三分位组相关系数分别为 0.48、0.68、0.45(交互作用 P=0.69)。结论认为,尽管 COVID-19 大流行在美国的影响不均衡,医院大流行前后院内心脏骤停生存绩效仍呈良好相关,即使在照护较大比例黑人/西班牙裔患者的医院也是如此。

要点

  • 纳入 243 家医院、122,561 例院内心脏骤停(大流行前 57,601 例,大流行后 64,960 例),要求两个时期均参与注册至少 2 年且各期至少 20 例。
  • 大流行前平均风险标化出院生存率为 26.8%(SD 5.2%),大流行后为 21.7%(SD 5.5%)。
  • 医院大流行前后风险标化出院生存率相关系数为 0.55,提示绩效排名具有延续性。
  • 按黑人/西班牙裔患者比例三分位分组,相关系数上、中、下三分位分别为 0.48、0.68、0.45,交互作用 P=0.69。
  • 作者认为未来研究需要了解大流行前高绩效医院的哪些特征使许多医院在大流行后继续表现优异。

适用人群与场景

  • Get With The Guidelines®-复苏注册中,大流行前(2017-2019)和大流行后(2020 年 7 月-2022)均参与注册至少 2 年、且两个时期均至少有 20 例院内心脏骤停的医院。

研究设计与关键结果

  • 研究类型为基于 Get With The Guidelines®-复苏注册的分析,纳入 243 家医院、122,561 例院内心脏骤停(大流行前 57,601 例,大流行后 64,960 例)。
  • 采用以医院为随机效应、调整患者和骤停特征的多变量层次模型计算风险标化出院生存率。
  • 大流行前平均风险标化出院生存率为 26.8%(SD 5.2%),大流行后为 21.7%(SD 5.5%)。
  • 医院大流行前后风险标化出院生存率相关系数为 0.55。
  • 按黑人/西班牙裔院内心脏骤停患者比例三分位分组,上、中、下三分位组相关系数分别为 0.48、0.68、0.45,交互作用 P=0.69。

证据类型、等级与局限

  • 证据类型:基于 Get With The Guidelines®-复苏注册的分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,未来研究需要了解大流行前高绩效医院的哪些特征使许多医院在大流行后继续表现优异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Survival for in-hospital cardiac arrest (IHCA) has declined since the COVID-19 pandemic. Because the burden of COVID-19 was uneven throughout the U.S., it remains unknown if top-performer hospitals in IHCA survival have remained top-performers since the pandemic.

METHODS: Within Get With The Guidelines®-Resuscitation, we identified hospitals with at least 2 years of registry participation pre-pandemic (2017-2019) and post-pandemic (July 2020-2022) and with at least 20 IHCA cases in both periods. Using multivariable hierarchical models with hospital as a random effect and adjusting for patient and arrest characteristics, we calculated risk-standardized survival rates to discharge (RSSR) for IHCA at each hospital during the pre- and post-pandemic periods. We then assessed the correlation between a hospital's pre-pandemic and post-pandemic RSSR for IHCA, and whether the correlation differed by the proportion of Black or Hispanic IHCA patients at each hospital.

RESULTS: A total of 243 hospitals were included, comprising 122,561 IHCAs (pre-pandemic: 57,601; post-pandemic: 64,960). Pre-pandemic, the mean RSSR was 26.8% (SD, 5.2%) whereas the mean RSSR post-pandemic was 21.7% (SD, 5.5%). There was good correlation between a hospital's pre- and post-pandemic RSSR: correlation of 0.55. When hospitals were categorized into tertiles based on the proportion of their IHCA patients who were Black or Hispanic, this correlation remained similar: 0.48, 0.68, and 0.45 (interaction P-value: 0.69) for hospitals in the upper, middle and lower tertiles, respectively.

CONCLUSION: Although the COVID-19 pandemic affected the U.S. unevenly, there was good correlation in a hospital's performance for IHCA survival before and after the pandemic, even at hospitals caring for a larger proportion of Black and Hispanic patients. Future studies are needed to understand what characteristics of high-performing hospitals pre-pandemic allowed many to continue to excel in the post-pandemic period.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Khan MS, Kennedy KF, Chan PS, et al. In-hospital cardiac arrest survival before and after the COVID-19 pandemic: Have higher performing hospitals stayed high-performing? Resuscitation. 2024. PMID: 39174001. doi:10.1016/j.resuscitation.2024.110374

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。